MedTrace Logo

High Dose Inspiratory Muscle Training in LOPD

NCT05431127 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-10-01

No results posted yet for this study

Summary

Study Objectives: 1) assess the safety and feasibility of high-dose inspiratory muscle training (IMT) delivered remotely in Late-onset Pompe Disease (LOPD) and 2) determine its effects on respiratory and patient-reported outcomes.

Conditions

  • Late-Onset Pompe Disease
  • Lysosomal Disease

Interventions

DEVICE

IMT therapy using the Pr02 mobile device

Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Harrison Jones, PhD · Duke University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-19
Primary Completion
2025-01-01
Completion
2025-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05431127 on ClinicalTrials.gov